{
    "clinical_study": {
        "@rank": "159914", 
        "arm_group": {
            "arm_group_label": "Lactobacillus brevis CD2 lozenges", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "A pilot  study on efficacy of Lactobacillus CD2 lozenges in preventing oral mucositis (OM)\n      by high-dose chemotherapy  with autologous hematopoietic stem cell transplantation. To test\n      whether the probiotic Lactobacillus brevis CD2 lozenges can reduce the incidence and\n      severity of high-dose chemotherapy conditioning regimen induced OM in patients undergoing\n      HSCT.\n\n      Clinical activity will be defined as reduction in the incidence of chemotherapy induced OM\n      in the patients undergoing HSCT."
        }, 
        "brief_title": "Lactobacillus Brevis CD2 Preventing Oral Mucositis", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Mucositis", 
        "condition_browse": {
            "mesh_term": [
                "Stomatitis", 
                "Mucositis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age between 18 and 65 years\n\n          -  Karnofsky Performance Score \u2265 70%.\n\n          -  Confirmed histological diagnosis of multiple myeloma for which HSCT is as  approved\n             modality of therapy\n\n          -  Patients eligible to receive high-dose chemotherapy as part of conditioning  regimen\n\n          -  Concomitant co morbid condition if present, controlled by ongoing treatments (e.g.\n             hypertension, diabetes and so on)\n\n          -  Serum creatinine < 1.8mg/dl\n\n          -  Total bilirubin  < 2mg/dl\n\n          -  Liver enzymes within three times of normal limit\n\n          -  Expected survival > 6 months.\n\n        Exclusion Criteria:\n\n          -  Pregnant women and lactating mothers\n\n          -  Patients with history of HIV infection\n\n          -  Patients who have taken any other investigational product in last 4 weeks\n\n          -  Patients having untreated symptomatic dental infection\n\n          -  Patients with WHO Grade 3 or 4 oral Mucositis\n\n          -  Other serious concurrent illness\n\n          -  Inconclusive hematological diagnosis\n\n          -  Patients with signs and symptoms of systemic infections\n\n          -  Patient's/guardian's refusal to sign informed consent"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "10", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 6, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02085694", 
            "org_study_id": "001/14"
        }, 
        "intervention": {
            "arm_group_label": "Lactobacillus brevis CD2 lozenges", 
            "intervention_name": "Lactobacillus brevis CD2", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 8, 2014", 
        "location": {
            "contact": {
                "email": "p.chiusolo@rm.unicatt.it", 
                "last_name": "Patrizia Chiusolo, MD", 
                "phone": "0039-0630155300"
            }, 
            "contact_backup": {
                "email": "sabrina_giammarco@libero.it", 
                "last_name": "Sabrina Giammarco, MD", 
                "phone": "0039-0630155300"
            }, 
            "facility": {
                "address": {
                    "city": "Rome", 
                    "country": "Italy", 
                    "zip": "00168"
                }, 
                "name": "Policlinico Universitario \"A. GEMELLI\""
            }, 
            "investigator": [
                {
                    "last_name": "Patrizia Chiusolo, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Sabrina Giammarco, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Italy"
        }, 
        "official_title": "A Pilot Study on the Efficacy of Lactobacillus Brevis CD2 Lozenges in Preventing Oral Mucositis by High-dose Chemotherapy With Autologous Hematopoietic Stem Cell Transplantation", 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Italy: Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "COMMON TERMINOLOGY CRITERIA FOR ADVERSE EVENTS v4.03 (CTCAE) for evaluation of change in oral mucositis", 
            "safety_issue": "No", 
            "time_frame": "days -14;-7; 0;+7;+14;+21"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02085694"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Catholic University of the Sacred Heart", 
            "investigator_full_name": "sabrina giammarco", 
            "investigator_title": "MD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "COMMON TERMINOLOGY CRITERIA FOR ADVERSE EVENTS v4.03 (CTCAE) to determine the incidence of Grade I and II OM", 
            "safety_issue": "No", 
            "time_frame": "days -14;-7; 0; +7;+14; +21"
        }, 
        "source": "Catholic University of the Sacred Heart", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Catholic University of the Sacred Heart", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}